D | OEI Subject Index

Data Banks/Data Systems

• see also: National Practitioner Data Bank
• CDC Found Ways To Use Data To Understand and Address COVID-19 Health Disparities, Despite Challenges With Existing Data OEI-05-20-00540
• Inaccuracies in Medicare's Race and Ethnicity Data Hinder the Ability To Assess Health Disparities OEI-02-21-00100
• National Review of Opioid Prescribing in Medicaid Is Not Yet Possible (OEI-05-18-00480)
• National Background Check Program for Long Term Care Providers: Assessment of State Programs Concluded Between 2013 and 2016 (OEI-07-16-00160)
• States Follow a Common Framework in Responding to Breaches of Medicaid Data (OEI-09-16-00210)
• Medicare Advantage Encounter Data Show Promise for Program Oversight, But Improvements Are Needed (OEI-03-15-00060)
• Potential Misclassifications Reported by Drug Manufacturers May Have Led to $1 Billion in Lost Medicaid Rebates (OEI-03-17-00100)
• T-MSIS Data Not Yet Available for Overseeing Medicaid (OEI-05-15-00050)
• CMS Validated Hospital Inpatient Quality Reporting Program Data, But Should Use Additional Tools to Identify Gaming (OEI-01-15-00320)
• Data Inadequacies Undermine CMS's Oversight of the Inconsistency Resolution Process for the Federal Marketplace (OEI-01-14-00620)
• Hospitals Largely Reported Addressing Requirements for EHR Contingency Plans (OEI-01-14-00570)
• OCR Should Strengthen Its Oversight of Covered Entities' Compliance With the HIPAA Privacy Standards (OEI-09-10-00510)
• OCR Should Strengthen Its Followup of Breaches of Patient Health Information Reported by Covered Entities (OEI-09-10-00511)
• Not All States Reported Medicaid Managed Care Encounter Data as Required (OEI-07-13-00120)
• Federal Marketplace: Inadequacies in Contract Planning and Procurement (OEI-03-14-00230)
• Marketplaces Faced Early Challenges Resolving Inconsistencies With Applicant Data (OEI-01-14-00180)
• Improper Payments for Evaluation and Management Services Cost Medicare Billions in 2010 (OEI-04-10-00181)
• CMS System for Sharing Information About Terminated Providers Needs Improvement (OEI-06-12-00031)
• CMS Regularly Reviews Part C Reporting Requirements Data, But Its Followup and Use of the Data Are Limited (OEI-03-11-00720)
• Disclosure and Accounting of Protected Records by CMS Between 2006 and 2011 (OEI-09-11-00430)
• Progress in Electronic Health Record Implementation Through HRSA Grants to Health Center Controlled Networks (OEI-09-11-00380)
• Not All Recommended Fraud Safeguards Have Been Implemented in Hospital EHR Technology (OEI-01-11-00570)
• Early Outcomes Show Limited Progress for the Transformed Medicaid Statistical Information System (OEI-05-12-00610)
• Improvements Are Needed To Ensure Provider Enumeration and Medicare Enrollment Data Are Accurate, Complete, and Consistent (OEI 07-09-00440)
• Early Assessment Finds That CMS Faces Obstacles in Overseeing the Medicare EHR Incentive Program (OEI-05-11-00250)
• CMS Reporting to the Healthcare Integrity and Protection Data Bank (OEI-07-09-00292)
• Few Adverse Events in Hospitals Were Reported to State Adverse Event Reporting Systems (OEI-06-09-00092)
• Use of Electronic Health Record Systems in 2011 Among Medicare Physicians Providing Evaluation and Management Services (OEI-04-10-00184)
• The Medicare-Medicaid (Medi-Medi) Data Match Program (OEI-09-08-00370)
• Limited Oversight of Home Health Agency OASIS Data (OEI-01-10-00460)
• Lack of Data Regarding Physicians Opting Out of Medicare (OEI-07-11-00340)
• Hospital Incident Reporting Systems Do Not Capture Most Patient Harm (OEI-06-09-00091)
• Results-Based Systems for Public Health Programs, Volume 1: Lessons from State Initiatives (OEI-05-96-00260; 9/97)
• Results-Based Systems for Public Health Programs, Volume 2: State Case Studies (OEI-05-96-00261; 9/97)
• Surveillance and Utilization Review Subsystem Referrals (OEI-07-95-00030; 11/96)
• Implementation of State Child Support Certified Data Systems (OEI-04-96-00010; 4/97)

Dental and Dentists

• Most Children With Medicaid in Four States Are Not Receiving Required Dental Services (OEI-02-14-00490)
• Questionable Billing for Medicaid Pediatric Dental Services in California (OEI-02-14-00480)
• Questionable Billing for Medicaid Pediatric Dental Services in Indiana (OEI-02-14-00250)
• Questionable Billing for Medicaid Pediatric Dental Services in New York (OEI-02-12-00330)
• Improper Payments for Medicaid Pediatric Dental Services (OEI-04-04-00210)
• Children's Dental Services Under Medicaid: Access and Utilization (OEI-09-93-00240; 4/96)
• The Licensure of Out-of-State Dentists (OEI-01-92-00820; 8/93)
• State Dental Boards and Dental Discipline (OEI-01-92-00821; 8/93)
• State Licensure and Discipline of Dentists (OAI-01-88-00580; 8/88)

Detoxification Services

• see also: Substance Abuse
• Follow-up to Detoxification Services for Medicaid Beneficiaries (OEI-07-97-00270; 11/98)

Devices

• see Medical Devices and Equipment

Diagnosis Related Groups (DRGs)

• Medicare and Beneficiaries Pay More for Preadmission Services at Affiliated Hospitals Than at Wholly Owned Settings OEI-05-19-00380
• Inconsistencies in State Implementation of Correct Coding Edits May Allow Improper Medicaid Payments (OEI-09-14-00440)
• Medicare and Beneficiaries Could Realize Substantial Savings If the DRG Window Were Expanded (OEI-05-12-00480)
• Questionable Billing for Polysomnography Services (OEI-05-12-00340)
• Coding Trends of Medicare Evaluation and Management Services (OEI-04-10-00180)
• Medicare Hospital Prospective Payment System: How DRG Rates Are Calculated and Updated (OEI-09-00-00200; 08/01)
• Medicare Payments for DRG 014: Specific Cerebrovascular Disorders Except Transient Ischemic Attack (OEI-03-99-00240; 7/99)
• Medicare Payments for DRG 296: Nutritional and Miscellaneous Metabolic Disorders (OEI-03-98-00490; 4/99)
• Medicare Payments for Septicemia (OEI-03-98-00370; 4/99)
• Medicare Payments for DRG 475: Respiratory System Diagnosis with Ventilator Support (OEI- 03-98-00560; 1/99)
• Monitoring the Accuracy of Hospital Coding (OEI-01-98-00420; 1/99)
• Using Software to Detect Upcoding of Hospital Bills (OEI-01-97-00010; 8/98)
• DRG 79 Validation Study Update: Respiratory Infections and Inflammations (OEI-12-89-00193; 9/93)
• DRG 154 Validation: Stomach, Esophageal, and Duodenal (OEI-12-89-00196; 12/93)
• DRG 121 Validation: Circulatory Disorders (OEI-12-89-00194; 10/92)
• DRG 296 Validation: Metabolic Disorders (OEI-12-89-00195; 10/92)
• National DRG Validation Study Update: Summary Report (OEI-12-89-00190; 8/92)
• National DRG Validation Study Update: Technical Report (OEI-12-89-00191; 8/92)
• DRG 14 Validation Update: Specific Cerebrovascular Disorders Except Transient Ischemic Attacks (OEI-12-89-00192; 8/92)
• FY 1985 National DRG Validation Study: Peer Review Organization Coding Accuracy (OEI-12-90-00660; 8/90)
• DRG 468: Unrelated Operating Room Procedures (OAI-12-88-01170; 9/89)
• DRG 79: Respiratory Infection (OAI-12-88-01190; 7/89)
• National DRG Validation Study: Quality of Patient Care in Hospitals (OAI-09-88-00870; 8/89)
• DRG 87: Pulmonary Edema and Respiratory Failure (OAI-12-88-01200; 8/89)
• DRG 121: Circulatory Disorders with Acute Myocardial Infarction and Cardiovascular Complications (OAI-12-88-01210; 8/89)
• DRG 154: Stomach, Esophageal, and Duodenal Procedures (OAI-12-88-01160; 8/89)
• DRG 416: Septicemia (OAI-12-88-01180; 8/89)
• DRG 89: Simple Pneumonia and Pleurisy (OAI-12-88-01140; 6/89)
• National DRG Validation Study: Short Hospitalizations (OAI-05-88-00730; 5/89)
• National DRG Validation Study: Unnecessary Admissions to Hospitals (OAI-09-88-00880; 8/88)
• National DRG Validation Study: Coding Accuracy (OAI-12-88-01010; 2/88)
• National DRG Validation Study: Premature Discharges (OAI-05-88-00740; 2/88)
• Validation of DRG 14 (OAI-09-86-00052; 12/87)

Dialysis and Dialysis Facilities

• see: End-Stage Renal Disease

Dietary Supplements

• Dietary Supplements: Structure/Function Claims Fail To Meet Federal Requirements (OEI-01-11-00210)
• Dietary Supplements: Companies May Be Difficult To Locate in an Emergency (OEI-01-11-00211)
• Dietary Supplement Labels: Key Elements (OEI-01-01-00120; 03/03)
• Dietary Supplement Labels: An Assessment (OEI-01-01-00121; 03/03)
• Adverse Event Reporting System for Dietary Supplements: An Inadequate Safety Valve (OEI-01-00-00180; 04/01)

Disability

• National Background Check Program for Long-Term-Care Providers: An Interim Assessment OEI-07-20-00181
• Oversight of Quality of Care in Medicaid Home and Community Based Services Waiver Programs (OEI-02-08-00170)
• Employment Programs for Persons with Developmental Disabilities (OEI-07-98-00260; 8/99)
• Perspectives of Medicare Risk HMOs 1996: Beneficiaries With Functional Limitations, Comorbidities and Disabilities (OEI-06-95-00434; 8/98)
• Cost Containment for Medicaid Disability Programs (OEI-05-95-00400; 7/97)
• Using Social Security Records to Detect Inappropriate Medicare Payments for Work-Related Disability Expenses (OEI-06-89-00903; 8/94)
• Propriety of Physicians' Receipt of Federal Payments (OAI-06-86-00067; 10/86)

Disaster Relief

• Coping With Twin Disasters: HHS Response to the 1989 Hurricane and Earthquake (OEI-09-90-01040; 12/90)

Discharge

• see: Dumping

Discretionary Grants

• Time Extensions and Funding Supplements for OHDS Discretionary Grants (OEI-04-89-00801; 6/92)

Drug Abuse

• see: Substance Abuse

Drug Enforcement Administration (DEA)

• Drug Enforcement Administration Report to the National Practitioner Data Bank (OEI-12-96-00160; 3/97)

Drugs and Drug Industry

• Early Alert: Part B Payment Amount for Tezspire Included a Noncovered Self-Administered Version in 2023 OEI-BL-24-00030
• The Risk of Misuse and Diversion of Buprenorphine for Opioid Use Disorder in Medicare Part D Continues to Appear Low: 2022 OEI-02-24-00130
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Second Quarter of 2023 OEI-03-24-00040
• Congressional Mandate: Part B Payment Amounts for Two Drugs Included Noncovered Self Administered Versions in 2022 OEI-BL-22-00380
• Biosimilars Have Lowered Costs for Medicare Part B and Enrollees, but Opportunities for Substantial Spending Reductions Still Exist OEI-05-22-00140
• Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2021 Average Sales Prices OEI-03-23-00120
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the First Quarter of 2023 OEI-03-23-00100
• Part D Plans Generally Include Drugs Commonly Used by Dual-Eligible Enrollees: 2023 OEI-05-23-00130
• The Risk of Misuse and Diversion of Buprenorphine for Opioid Use Disorder Appears to Be Low in Medicare Part D OEI-02-22-00160
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Fourth Quarter of 2022 OEI-03-23-00090
• Some Skin Substitute Manufacturers Did Not Comply with New ASP Reporting Requirements OEI-BL-23-00010
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Third Quarter of 2022 OEI-03-23-00080
• Technical Assistance Brief: Implementation of Inflation-Indexed Rebates for Part B Drugs OEI-BL-23-00170
• Manufacturers May Need Additional Guidance To Ensure Consistent Average Sales Price Calculations OEI-BL-21-00330
• CMS Should Bolster Its Oversight of Manufacturer-Submitted Average Sales Price Data To Ensure Accurate Part B Drug Payments OEI-03-21-00390
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Second Quarter of 2022 OEI-03-23-00070
• Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2020 Average Sales Prices OEI-03-22-00170
• Opioid Overdoses and the Limited Treatment of Opioid Use Disorder Continue To Be Concerns for Medicare Beneficiaries OEI-02-22-00390
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the First Quarter of 2022 OEI-03-22-00210
• Part D Plan Preference for Higher-Cost Hepatitis C Drugs Led to Higher Medicare and Beneficiary Spending OEI-BL-21-00200
• Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles: 2022 OEI-05-22-00230
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Fourth Quarter of 2021 OEI-03-22-00200
• Medicare Part D and Beneficiaries Could Realize Significant Spending Reductions With Increased Biosimilar Use OEI-05-20-00480
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Third Quarter of 2021 OEI-03-22-00190
• Many Medicare Beneficiaries Are Not Receiving Medication to Treat Their Opioid Use Disorder OEI-02-20-00390
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Second Quarter of 2021 OEI-03-22-00060
• High-expenditure Medicare drugs often qualified for Orphan Drug Act incentives designed to encourage the development of treatments for rare diseases OEI-BL-20-00080
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the First Quarter of 2021 OEI-03-21-00080
• Concerns Persist about Opioid Overdoses and Medicare Beneficiaries' Access to Treatment and Overdose-Reversal Drugs OEI-02-20-00401
• Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles: 2021 OEI-05-21-00170
• Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2019 Average Sales Prices OEI-03-21-00130
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Fourth Quarter of 2020 OEI-03-21-00070
• CMS Could Improve the Data It Uses To Monitor Antipsychotic Drugs in Nursing Homes OEI-07-19-00490
• Trend Toward More Expensive Inpatient Hospital Stays in Medicare Emerged Before COVID-19 and Warrants Further Scrutiny OEI-02-18-00380
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Third Quarter of 2020 OEI-03-21-00060
• Opioid Use in Medicare Part D During the Onset of the COVID-19 Pandemic OEI-02-20-00400
• States Could Do More to Oversee Spending and Contain Medicaid Costs for Specialty Drugs OEI-03-17-00430
• Opioids in Medicaid: Concerns About Opioid Use Among Beneficiaries in Six Appalachian States OEI-05-19-00410
• Few Patients Received High Amounts of Opioids from IHS-Run Pharmacies OEI-05-18-00470
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Second Quarter of 2020 OEI-03-21-00050
• FDA's Risk Evaluation and Mitigation Strategies: Uncertain Effectiveness in Addressing the Opioid Crisis OEI-01-17-00510
• CMS Should Pursue Strategies To Increase the Number of At Risk Beneficiaries Acquiring Naloxone Through Medicaid OEI-BL-18-00360
• Some Manufacturers Reported Inaccurate Drug Product Data to CMS OEI-03-19-00200
• Opioid Use in Medicare Part D Continued To Decline in 2019, but Vigilance Is Needed as COVID-19 Raises New Concerns OEI-02-20-00320
• Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2018 Average Sales Prices OEI-03-20-00130
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the First Quarter of 2020 OEI-03-20-00060
• Loophole in Drug Payment Rule Continues To Cost Medicare and Beneficiaries Hundreds of Millions of Dollars
• Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles: 2020 OEI-05-20-00190
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Fourth Quarter of 2019 OEI-03-20-00050
• HHS OIG Toolkits for Calculating Opioid Levels and Identifying Patients At Risk of Misuse or Overdose
• Medicare Part D Beneficiaries at Serious Risk of Opioid Misuse or Overdose: A Closer Look OEI-02-19-00130
• States' Use of Grant Funding for a Targeted Response to the Opioid Crisis OEI-BL-18-00460
• Key Medicare Tools To Safeguard Against Pharmacy Fraud and Inappropriate Billing Do Not Apply to Part D OEI-02-15-00440
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Third Quarter of 2019 OEI-03-20-00040
• Ownership—But Not Physical Movement—of Selected Drugs Can Be Traced Through the Supply Chain OEI-05-17-00460
• Geographic Disparities Affect Access to Buprenorphine Services for Opioid Use Disorder OEI-12-17-00240
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Second Quarter of 2019 (OEI-03-20-00070)
• Opioid Use in Medicare Part D in Missouri (OEI-02-19-00391)
• Reasonable Assumptions in Manufacturer Reporting of AMPs and Best Prices (OEI-12-17-00130)
• Some Medicare Part D Beneficiaries Face Avoidable Extra Steps That Can Delay or Prevent Access to Prescribed Drugs (OEI-09-16-00411)
• Rebates for Brand Name Drugs in Part D Substantially Reduced the Growth in Spending from 2011 to 2015 (OEI-03-19-00010)
• National Review of Opioid Prescribing in Medicaid Is Not Yet Possible (OEI-05-18-00480)
• Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2017 Average Sales Prices (OEI-03-19-00260)
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the First Quarter of 2019 (OEI-03-19-00050)
• Opioid Use Decreased in Medicare Part D, While Medication-Assisted Treatment Increased (OEI-02-19-00390)
• Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles: 2019 (OEI-05-19-00220)
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Fourth Quarter of 2018 (OEI-03-19-00040)
• One Percent of Drugs With Medicaid Reimbursement Were Not FDA-Approved (OEI-03-17-00120)
• Concerns About Opioid Use in Medicare Part D in the Appalachian Region (OEI-02-18-00224)
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Third Quarter of 2018 (OEI-03-19-00030)
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Second Quarter of 2018 (OEI-03-19-00020)
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Third Quarter of 2017 (OEI-03-18-00150)
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the Fourth Quarter of 2017 (OEI-03-18-00270)
• Comparison of Average Sales Prices and Average Manufacturer Prices: Results for the First Quarter of 2018 (OEI-03-18-00280)
• Treatment Planning and Medication Monitoring Were Lacking for Children in Foster Care Receiving Psychotropic Medication (OEI-07-15-00380)
• Questionable Billing for Compounded Topical Drugs in Medicare Part D (OEI-02-16-00440)
• Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2016 Average Sales Prices (OEI-03-18-00120)
• Open Payments Data: Review of Accuracy, Precision, and Consistency in Reporting (OEI-03-15-00220)
• The MEDIC Produced Some Positive Results but More Could be Done to Enhance its Effectiveness (OEI-03-17-00310)
• Opioids in Ohio Medicaid: Review of Extreme Use and Prescribing (OEI-05-18-00010)
• Toolkit: Using Data Analysis To Calculate Opioid Levels and Identify Patients At Risk of Misuse or Overdose (OEI-02-17-00560)
• Opioid Use in Medicare Part D Remains Concerning (OEI-02-18-00220)
• Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles: 2018 (OEI-05-18-00240)
• Increases in Reimbursement for Brand-Name Drugs in Part D (OEI-03-15-00080)
• Drug Supply Chain Security: Dispensers Received Most Tracing Information (OEI-05-16-00550)
• Potential Misclassifications Reported by Drug Manufacturers May Have Led to $1 Billion in Lost Medicaid Rebates (OEI-03-17-00100)
• Excluding Noncovered Versions When Setting Payment for Two Part B Drugs Would Have Resulted in Lower Drug Costs for Medicare and its Beneficiaries (OEI-12-17-00260)
• CMS Ensured Nearly All Part D Drug Records Contained Valid Prescriber Identifiers in 2016 (OEI-03-17-00040)
• Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2015 Average Sales Prices  (OEI-03-17-00360)
• Drug Supply Chain Security: Wholesalers Exchange Most Tracing Information (OEI-05-14-00640)
• Calculation of Potential Inflation-Indexed Rebates For Medicare Part B Drugs 2017 (OEI-12-17-00180)
• Medicare Part B Drug Payments: Impact of Price Substitutions Based on 2014 Average Sales Prices (OEI 03-16-00540)
• Opioids in Medicare Part D: Concerns about Extreme Use and Questionable Prescribing (OEI-02-17-00250)
• Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles: 2017 (OEI-05-17-00160)
• High-Price Drugs Are Increasing Federal Payments for Medicare Part D Catastrophic Coverage (OEI-02-16-00270)
• CMS Should Address Medicare's Flawed Payment System for DME Infusion Drugs Report (OEI-12-16-00340)
• MACs Continue to Use Different Methods to Determine Drug Coverage (OEI-03-13-00450)
• Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles: 2016 (OEI-05-16-00090)
• State Efforts to Exclude 340B Drugs from Medicaid Managed Care Rebates (OEI-05-14-00430)
• Part B Payments for 340B Purchased Drugs (OEI-12-14-00030)
• States' Collection of Rebates for Drugs Paid Through Medicaid Managed Care Organizations Has Improved (OEI-05-14-00431)
• Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles: 2015 (OEI-05-15-00120)
• FDA Has Made Progress on Oversight and Inspections of Manufacturers of Generic Drugs (OEI-01-13-00600)
• Medicaid Rebates for Brand-Name Drugs Exceeded Part D Rebates by a Substantial Margin (OEI-03-13-00650)
• Implementing OIG Recommendation Could Have Reduced Payments for DME Infusion Drugs by Hundreds of Millions of Dollars (OEI-12-15-00110)
• Second-Generation Antipsychotic Drug Use Among Medicaid-Enrolled Children: Quality-of-Care Concerns (OEI-07-12-00320)
• Comparing Average Sales Prices and Average Manufacturer Prices for Medicare Part B Drugs: An Overview of 2013 (OEI-03-14-00520)
• Medicare's Oversight of Compounded Pharmaceuticals Used in Hospitals (OEI-01-13-00400)
• States' Collection of Offset and Supplemental Medicaid Rebates (OEI-03-12-00520)
• Medicare Paid for HIV Drugs for Deceased Beneficiaries (OEI-02-11-00172)
• Drug Compendia Publishers Maintain Transparent Processes for Evaluating Anticancer Drug Therapies and Identifying Potential Conflicts (OEI-07-13-00220)
• Manufacturer Safeguards May Not Prevent Copayment Coupon Use for Part D Drugs (OEI-05-12-00540)
• Questionable Billing for Medicaid Pediatric Dental Services in Louisiana (OEI-02-14-00120)
• Medicaid Drug Rebate Dispute Resolution Could Be Improved (OEI-05-11-00580)
• Part D Beneficiaries With Questionable Utilization Patterns for HIV Drugs (OEI-02-11-00170)
• Limitations in Manufacturer Reporting of Average Sales Price Data for Part B Drugs (OEI-12-13-00040)
• Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles: 2014 (OEI-05-14-00170)
• Compounded Drugs Under Medicare Part B: Payment and Oversight (OEI-03-13-00270)
• Annual Fee on Branded Prescription Drug Companies Under the Affordable Care Act (OEI-03-12-00560)
• Update: Medicare Payments for End Stage Renal Disease Drugs (OEI-03-12-00550)
• Comparing Average Sales Prices and Average Manufacturer Prices for Medicare Part B Drugs: An Overview of 2012 (OEI-03-13-00570)
• Less Than Half of Part D Sponsors Voluntarily Reported Data on Potential Fraud and Abuse (OEI-03-13-00030)
• Contract Pharmacy Arrangements in the 340B Program (OEI-05-13-00431)
• Medicare Could Collect Billions If Pharmaceutical Manufacturers Were Required To Pay Rebates for Part B Drugs (OEI-12-12-00260)
• Medicaid Drug Pricing in State Maximum Allowable Cost Programs (OEI-03-11-00640)
• Medicare Inappropriately Paid for Drugs Ordered by Individuals Without Prescribing Authority (OEI-02-09-00608)
• Prescribers With Questionable Patterns in Medicare Part D (OEI-02-09-00603)
• Part D Plans Generally Include Drugs Commonly Used by Dual Eligible: 2013 Report (OEI-05-13-00090)
• High-Risk Compounded Sterile Preparations and Outsourcing by Hospitals That Use Them (OEI-01-13-00150)
• Gaps in Oversight of Conflicts of Interest in Medicare Prescription Drug Decisions (OEI-05-10-00450)
• Comparison of Average Sales Prices and Average Manufacturer Prices: An Overview of 2011 (OEI-03-12-00670)
• Part B Payments for Drugs Infused Through Durable Medical Equipment (OEI-12-12-00310)
• FDA Lacks Comprehensive Data To Determine Whether Risk Evaluation and Mitigation Strategies Improve Drug Safety (OEI-04-11-00510)
• MEDIC Benefit Integrity Activities in Medicare Parts C and D (OEI-03-11-00310)
• Comparison of Second-Quarter 2012 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Fourth Quarter 2012 (OEI-03-13-00100)
• Comparison of First-Quarter 2012 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Third Quarter 2012 (OEI-03-12-00730)
• Least Costly Alternative Policies: Impact on Prostate Cancer Drugs Covered Under Medicare Part B (OEI-12-12-00210)
• Analyzing Changes to Medicaid Federal Upper Limit Amounts (OEI-03-11-00650)
• Inappropriate Medicare Part D Payments for Schedule II Drugs Billed as Refills (OEI-02-09-00605)
• States Collection of Medicaid Rebates for Drugs Paid Through Medicaid Managed Care Organizations (OEI-03-11-00480)
• Comparison of Fourth-Quarter 2011 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Second Quarter 2012 (OEI-03-12-00410)
• Nursing Facility Assessments and Care Plans for Residents Receiving Atypical Antipsychotic Drugs (OEI-07-08-00151)
• Louisiana Medicaid Payments and Services Related to Hurricanes Katrina and Rita: Data Compendium (OEI-05-07-00300)
• Part D Plans Generally Include Drugs Commonly Used by Dual Eligibles: 2012 (OEI-05-12-00060)
• Retail Pharmacies With Questionable Part D Billing (OEI-02-09-00600)
• Medicare Payments for Drugs Used To Treat Wet Age Related Macular Degeneration (OEI-03-10-00360)
• Comparison of Average Sales Prices to Widely Available Market Prices for Selected Drugs (OEI-03-10-00280)
• Comparison of Second-Quarter 2011 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Fourth Quarter 2011 (OEI-03-12-00020)
• Audits of Medicare Prescription Drug Plan Sponsors (OEI-03-09-00330)
• Ensuring That Medicare Part D Reimbursement Is Limited to Drugs Provided for Medically Accepted Indications (OEI-07-08-00152)
• Zone Program Integrity Contractors' Data Issues Hinder Effective Oversight (OEI-03-09-00520)
• Comparison of Average Sales Prices and Average Manufacturer Prices: An Overview of 2010 (OEI-03-11-00410)
• Medicaid Brand-Name Drugs: Rising Prices Are Offset by Manufacturer Rebates (OEI-03-10-00260)
• Higher Rebates for Brand-Name Drugs Result in Lower Costs for Medicaid Compared to Medicare Part D (OEI-03-10-00320)
• Comparison of First-Quarter 2011 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Third Quarter 2011 (OEI-03-11-00540)
• Medicare Prescription Drug Sponsors' Training To Prevent Fraud, Waste, and Abuse (OEI-01-10-00060)
• Comparison of Fourth-Quarter 2010 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Second Quarter 2011 (OEI-03-11-00360)
• Replacing Average Wholesale Price: Medicaid Drug Payment Policy (OEI-03-11-00060)
• States' Collection of Medicaid Rebates for Physician-Administered Drugs (OEI-03-09-00410)
• State Medicaid Policies and Oversight Activities Related to 340B-Purchased Drugs (OEI-05-09-00321)
• Part D Plans Generally Cover Drugs Commonly Used By Dual Eligibles (OEI-05-10-00390)
• Comparison of Average Sales Prices and Average Manufacturer Prices: An Overview of 2009 (OEI-03-10-00380)
• Concerns With Rebates in the Medicare Part D Program (OEI-02-08-00050)
• Comparison of Second-Quarter 2010 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Fourth Quarter 2010 (OEI-03-11-00030)
• Medicare Payments for Newly Available Generic Drugs (OEI-03-09-00510)
• Questionable Billing for Brand-Name Inhalation Drugs in South Florida (OEI-03-09-00530)
• FDA's Approval Status of Drugs Paid for by Medicaid (OEI-03-08-00500)
• Medicare Part D Pharmacy Discounts for 2008 (OEI-02-10-00120)
• Comparison of First-Quarter 2010 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Third Quarter 2010 (OEI-03-10-00440)
• Payment for Drugs Under the Hospital Outpatient Prospective Payment System (OEI-03-09-00420)
• Drug Manufacturers? Noncompliance With Average Manufacturer Price Reporting Requirements (OEI-03-09-00060)
• Comparison of Fourth-Quarter 2009 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Second Quarter 2010 (OEI-03-10-00350)
• Comparison of Third-Quarter 2009 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for First Quarter 2010 (OEI-03-10-00150)
• Comparison of Average Sales Prices and Average Manufacturer Prices: An Overview of 2008 (OEI-03-09-00350)
• Average Sales Prices: Manufacturer Reporting and CMS Oversight (OEI-03-08-00480)
• Comparison of Second-Quarter 2009 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Fourth Quarter 2009 (OEI-03-09-00640)
• Comparison of Fourth-Quarter 2008 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Second Quarter 2009 (OEI-03-09-00340)
• Comparison of First-Quarter 2009 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Third Quarter 2009 (OEI-03-09-00490)
• A Comparison of Medicaid Federal Upper Limit Amounts to Acquisition Costs, Medicare Payment Amounts, and Retail Prices (OEI-03-08-00490)
• Outlier Average Manufacturer Prices in the Federal Upper Limit Program (OEI-03-07-00740)
• Medicare Drug Integrity Contractors? Identification of Potential Part D Fraud and Abuse (OEI-03-08-00420)
• Beneficiary Utilization of Albuterol and Levalbuterol Under Medicare Part B (OEI-03-07-00440)
• Accuracy of Drug Categorizations for Medicaid Rebates (OEI-03-08-00300)
• Aberrant Claim Patterns for Inhalation Drugs in South Florida (OEI-03-08-00290)
• Comparison of Third-Quarter 2008 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for First Quarter 2009 (OEI-03-09-00150)
• Comparing Pharmacy Reimbursement: Medicare Part D to Medicaid (OEI-03-07-00350)
• Comparison of Second-Quarter 2008 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Fourth Quarter 2008 (OEI-03-09-00050)
• Comparison of First-Quarter 2008 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Third Quarter 2008 (OEI-03-08-00530)
• Comparison of Average Sales Prices and Average Manufacturer Prices: An Overview of 2007 (OEI-03-08-00450)
• Comparing Special Needs Plan Beneficiaries to Other Medicare Advantage Prescription Drug Plan Beneficiaries (OEI-05-07-00490)
• Centers for Medicare & Medicaid Services Audits of Medicare Part D Bids (OEI-05-07-00560)
• Oversight of Prescription Drug Plan Sponsors? Compliance Plans (OEI-03-08-00230)
• Medicare Drug Plan Sponsors? Identification of Potential Fraud and Abuse (OEI-03-07-0380)
• Medicare Payment for Irinotecan (OEI-03-08-00310)
• Comparison of Fourth-Quarter 2007 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Second-Quarter 2008 (OEI-03-08-00340)
• A Comparison of Average Sales Prices to Widely Available Market Prices for Inhalation Drugs (OEI-03-07-00190)
• Comparison of Third-Quarter 2007 Average Sales Prices to Average Manufacturer Prices: Impact on Medicare Reimbursement for First-Quarter 2008 (OEI-03-08-00130)
• Comparison of Second-Quarter 2007 Average Sales Prices and Average Manufacturer Prices: Impact on Medicare Reimbursement for Fourth Quarter 2007 (OEI-03-08-00010)
• Generic Drug Utilization in the Medicare Part D Program (OEI-05-07-00130)
• Comparison of First-Quarter 2007 Average Sales Prices to Average Manufacturer Prices: Impact on Medicare Reimbursement for Third Quarter 2007 (OEI-03-07-00530)
• Comparison of Third-Quarter 2006 Average Sales Prices to Average Manufacturer Prices: Impact on Medicare Reimbursement for First Quarter 2007 (OEI-03-07-00140)
• Retail Pharmacy Participation in Medicare Part D Prescription Drug Plans in 2006 (OEI-05-06-00320)
• Deficit Reduction Act of 2005: Impact on the Medicaid Federal Upper Limit Program (OEI-03-06-00400)
• Examining Fluctuations in Average Manufacturer Prices (OEI-03-06-00350)
• States? Use of New Drug Pricing Data in the Medicaid Program (OEI-03-06-00490)
• Intravenous Immune Globulin: Medicare Payment and Availability (OEI-03-05-00404)
• Comparison of Fourth Quarter 2005 Average Sales Prices to Average Manufacturer Prices: Impact on Medicare Reimbursement for Second Quarter 2006 (OEI-03-06-00370; 07/06)
• Review of 340B Prices (OEI-05-02-00073; 07/06)
• Generic Drug Utilization in State Medicaid Programs (OEI-05-05-00360; 07/06)
• A Comparison of Average Sales Price to Widely Available Market Prices: Fourth Quarter 2005 (OEI-03-05-00430; 06/06)
• Monitoring Medicare Part B Drug Prices: A Comparison of Average Sales Prices to Average Manufacturer Prices (OEI-03-04-00430; 05/06)
• Medicare Reimbursement for New End Stage Renal Disease Drugs (OEI-03-06-00200; 03/06)
• Calculation of Volume-Weighted Average Sales Price for Medicare Part B Prescription Drugs (OEI-03-05-00310; 03/06)
• Deficiencies in the Oversight of the 340B Drug Pricing Program (OEI-05-02-00072; 10/05)
• Review of Services Provided by Inhalation Drug Suppliers (OEI-01-05-00090; 09/05)
• How Inflated Published Prices Affect Drugs Considered for the Federal Upper Limit List (OEI-03-05-00350; 09/05)
• Comparison of Medicaid Federal Upper Limit Amounts to Average Manufacturer Prices (OEI-03-05-00110; 06/05)
• Medicaid Drug Price Comparisons: Average Manufacturer Price to Published Prices (OEI-05-05-00240; 06/05)
• Medicaid Drug Price Comparison: Average Sale Price to Average Wholesale Price (OEI-03-05-00200; 06/05)
• Addition of Qualified Drugs to the Medicaid Federal Upper Limit List (OEI-03-04-00320; 12/04)
• Variation in State Medicaid Drug Prices (OEI-05-02-00681; 09/04)
• Deficiencies in the 340B Drug Discount Program's Database (OEI-05-02-00071; 06/04)
• Appropriateness of 340B Drug Prices (OEI-05-02-00070; 06/04)
• Medicare Reimbursement for Existing End-Stage Renal Disease Drugs (OEI-03-04-00120; 05/04)
• Medicaid Rebates for Physician-Administered Drugs (OEI-03-02-00660; 04/04)
• Omission of Drugs from the Federal Upper Limit List in 2001 (OEI-03-02-00670; 03/04)
• Medicare Reimbursement for Lupron (OEI-03-03-00250; 01/04)
• Update: Excessive Medicare Reimbursement for Albuterol (OEI-03-03-00510; 01/04)
• Update: Excessive Medicare Reimbursement for Ipratropium Bromide (OEI-03-03-00520; 01/04)
• State Strategies to Contain Medicaid Drug Costs (OEI-05-02-00680)
• Medicaid's Mental Health Drug Expenditures (OEI-05-02-00080; 08/03)
• FDA's Review Process for New Drug Applications: A Management Review (OEI-01-01-00590; 03/02)
• Excessive Medicare Reimbursement for Ipratropium Bromide (OEI-03-01-00411; 03/02)
• Psychotropic Drug Use in Nursing Homes (OEI-02-00-00490; 11/01)
• Psychotropic Drug Use in Nursing Homes: Supplemental Information?10 Case Studies (OEI-02-00-00491; 11/01)
• Medicaid's Use of Revised Average Wholesale Prices (OEI-03-01-00010; 10/01)
• Medicaid Recovery of Pharmacy Payments from Liable Third Parties (OEI-03-00-00030; 08/01)
• Cost Containment of Medicaid HIV/AIDS Drug Expenditures (OEI-05-99-00611; 07/01)
• The Orphan Drug Act: Implementation and Impact (OEI-09-00-00380; 05/01)
• Adverse Event Reporting System for Dietary Supplements: An Inadequate Safety Valve (OEI-01-00-00180; 04/01)
• Medicare Reimbursement of Prescription Drugs (OEI-03-00-00310; 1/01)
• AIDS Drug Assistance Program Cost Containment Strategies (OEI-05-99-00610; 9/00)
• Medicare Reimbursement of End Stage Renal Disease Drugs (OEI-03-00-00020; 6/00)
• Medicare Reimbursement of Albuterol (OEI-03-00-00311; 6/00)
• Medicare Licensing Requirements for Prescription Drug Suppliers (OEI-07-98-00460; 5/99)
• FDA Warning Letters: Trends and Perspectives (OEI-09-97-00380; 2/99)
• FDA Warning Letters: Timeliness And Effectiveness (OEI-09-97-00381; 2/99)
• Excessive Medicare Payments for Prescription Drugs (OEI-03-97-00290; 12/97)
• Comparing Drug Reimbursement: Medicare and Department of Veterans Affairs (OEI-03-97-00293; 11/98)
• The Impact of High-Priced Generic Drugs on Medicare and Medicaid (OEI-03-97-00510; 8/98)
• Prescription Drug Use In Nursing Homes - Report 1 - An Introduction Based on Texas (OEI-06-96-00080; 11/97)
• Prescription Drug Use In Nursing Homes - Report 2 - An Inside View by Consultant Pharmacists (OEI-06-96-00081; 11/97)
• Prescription Drug Use In Nursing Homes - Report 3 - A Pharmaceutical Review and Inspection Recommendations (OEI-06-96-00082; 11/97)
• Questionable Practices Involving Nebulizer Drug Therapy (OEI-03-94-00391; 3/97)
• Payments for Prescription Drugs Used with Nebulizers (OEI-03-94-00390; 2/96)
• A Comparison of Albuterol Sulfate Prices (OEI-03-94-00392; 6/96)
• Suppliers' Acquisition Costs for Albuterol Sulfate (OEI-03-94-00393; 6/96)
• Appropriateness of Medicare Prescription Drug Allowances (OEI-03-95-00420; 5/96)
• Postmarketing Studies of Prescription Drugs (OEI-03-94-00760; 5/96)
• Medicaid Payments for Less-Than-Effective Drugs (OEI-03-94-00090; 8/94)
• Medicaid Program Savings Through the Use of Therapeutically Equivalent Drugs (OEI-03-94-00080; 7/94)
• Multiple Copy Prescription Programs: State Experiences (OEI-12-91-00490; 6/92)
• Comparison of Reimbursement Prices for Multiple-Source Prescription Drugs in the United States and Canada (OEI-03-91-00470; 8/91)
• Strategies to Reduce Medicaid Drug Expenditures (OEI-12-90-00800; 3/91)
• Reducing Medication Problems of the Elderly (OEI-04-89-89122; 11/90)
• Medication Regimens: Causes of Non-Compliance (OEI-04-89-89121; 6/90)
• Rural Georgia Pharmacy Closures (OAI-04-90-00990; 12/89)
• Medicare Drug Utilization Review (OAI-01-88-00980; 5/89)
• Prescription Drug Promotion Involving Payments and Gifts: Physicians' Perspectives (OEI-01-90-00481; 7/92)
• Prescription Drug Advertisements in Medical Journals (OEI-01-90-00482; 6/92)
• FDA's Urgent Notices (OEI-07-94-00631; 7/96)
• OIGOversight of FDA Activities: A Summary Report (OEI-12-92-00200; 2/92)
• The FDA Prescription Drug File (OEI-03-90-02300; 11/91)
• Computer Support for FDA's Drug Registration and Listing System (OEI-03-90-02301; 11/91)
• Hospital Reporting of Adverse Drug Reactions (OEI-12-90-01000; 8/91)
• Promotion of Prescription Drugs Through Payments and Gifts (OEI-01-90-00480; 8/91)
• Symposium on Drug Utilization Review Issues - Summary Report (OEI-01-89-89010; 8/90)
• Implementing User Fees in the Food and Drug Administration: A Case Study (OEI-12-90-02020; 7/90)
• Perspectives of Drug Manufacturers: Abbreviated New Drug Applications (OEI-12-90-00770; 2/90)
• Perspectives of Drug Manufacturers: Investigational New Drug and New Drug Applications (OEI-12-90-00771; 2/90)
• Physician Drug Dispensing: An Overview of State Regulation (OAI-01-88-00590; 5/89)

Drug Utilization Review

• see: Drugs and Drug Industry

Drug Use Review Programs

• Medicaid Drug Use Review Programs: Lessons Learned by States (OEI-01-92-00800; 5/95)

Dumping

• see also: Hospitals
• Patient Dumping After COBRA: U.S. Department of Health and Human Services Response to Complaints (OAI-12-88-00831; 12/88)
• Patient Dumping After COBRA: Assessing the Incidence and the Perspectives of Health Care Professionals (OAI-12-88-00830; 8/88)
• Inappropriate Discharges and Transfers (OAI-05-86-00050; 3/86)
• Public Health Service's Oversight of the Hill-Burton Program (OEI-05-90-00260; 8/92)
• Office for Civil Rights' Oversight of the Hill-Burton Program (OEI-05-90-00261; 8/92)

Durable Medical Equipment Regional Carriers (DMERC)

• see also: Medical Devices and Equipment
• Medicare Part B Allowances for Wound Care Supplies (OEI-03-94-00793; 6/98)
• Medicare Beneficiary Satisfaction with DMERC Services (OEI-02-96-00200; 6/97)

Durable Medical Equipment

• see: Medical Devices and Equipment